Key result
Bridging anticoagulation is only indicated for patients with high or moderate thromboembolic risk due to the often underestimated risk of bleeding.
Why the study?
When bridging anticoagulation, the risk of bleeding compared to thromboembolic risk is often underestimated.
Bridging anticoagulation should be reserved for patients with high thromboembolic risk, and interdisciplinary discussion is recommended for those on dual antiplatelet therapy.
May support limiting bridging to high/moderate-risk patients; leaves open prospective validation of bleeding thresholds.
Abtract When bridging anticoagulation, the risk of bleeding - compared to the thromboembolic risk - is often underestimated. Bridging is only indicated in case of high (and possibly moderate) thromboembolic risk. When bridging patients with indication for dual antiplatelet therapy, an interdisciplinary case discussion should take place to assess the risk.
No takes yet. Share an insight, caveat, or question.
Altiok et al. (2022) studied this question. Bridging anticoagulation is only indicated for patients with high or moderate thromboembolic risk due to the often underestimated risk of bleeding.
Synapse has enriched 5 related papers. Consider them for comparative context: